164 related articles for article (PubMed ID: 25418354)
1. The prognostic and predictive value of solid subtype in invasive lung adenocarcinoma.
Zhang Y; Li J; Wang R; Li Y; Pan Y; Cai D; Hu H; Li H; Ye T; Luo X; Zhang Y; Li B; Shen L; Sun Y; Chen H
Sci Rep; 2014 Nov; 4():7163. PubMed ID: 25418354
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Factors for Survival After Recurrence in Patients With Completely Resected Lung Adenocarcinoma: Important Roles of Epidermal Growth Factor Receptor Mutation Status and the Current Staging System.
Kudo Y; Shimada Y; Saji H; Kato Y; Yoshida K; Matsubayashi J; Nagase S; Kakihana M; Kajiwara N; Ohira T; Nagao T; Ikeda N
Clin Lung Cancer; 2015 Nov; 16(6):e213-21. PubMed ID: 25986624
[TBL] [Abstract][Full Text] [Related]
3. EGFR and TTF-1 gene amplification in surgically resected lung adenocarcinomas: clinicopathologic significance and effect on response to EGFR-tyrosine kinase inhibitors in recurred cases.
Lee JS; Kim HR; Lee CY; Shin M; Shim HS
Ann Surg Oncol; 2013 Sep; 20(9):3015-22. PubMed ID: 23525704
[TBL] [Abstract][Full Text] [Related]
4. ANCCA protein expression is a novel independent poor prognostic marker in surgically resected lung adenocarcinoma.
Zhang Y; Sun Y; Li Y; Fang Z; Wang R; Pan Y; Hu H; Luo X; Ye T; Li H; Wang L; Chen H; Ji H
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S577-82. PubMed ID: 23775406
[TBL] [Abstract][Full Text] [Related]
5. Solid predominant histologic subtype and early recurrence predict poor postrecurrence survival in patients with stage I lung adenocarcinoma.
Luo J; Wang R; Han B; Zhang J; Zhao H; Fang W; Luo Q; Yang J; Yang Y; Zhu L; Chen T; Cheng X; Huang Q; Wang Y; Zheng J; Chen H
Oncotarget; 2017 Jan; 8(4):7050-7058. PubMed ID: 27732964
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of epidermal growth factor receptor gene mutation in resected lung adenocarcinoma.
Deng C; Zhang Y; Ma Z; Fu F; Deng L; Li Y; Chen H
J Thorac Cardiovasc Surg; 2021 Sep; 162(3):664-674.e7. PubMed ID: 32747123
[TBL] [Abstract][Full Text] [Related]
7. Solid Predominant Histologic Subtype in Resected Stage I Lung Adenocarcinoma Is an Independent Predictor of Early, Extrathoracic, Multisite Recurrence and of Poor Postrecurrence Survival.
Ujiie H; Kadota K; Chaft JE; Buitrago D; Sima CS; Lee MC; Huang J; Travis WD; Rizk NP; Rudin CM; Jones DR; Adusumilli PS
J Clin Oncol; 2015 Sep; 33(26):2877-84. PubMed ID: 26261257
[TBL] [Abstract][Full Text] [Related]
8. A comprehensive evaluation of clinicopathologic characteristics, molecular features and prognosis in lung adenocarcinoma with solid component.
Li J; You W; Zheng D; Yan B; Ma X; Pan Y; Zhang Y; Li Y; Shen X; Cheng X; Sun Y; Chen H
J Cancer Res Clin Oncol; 2018 Apr; 144(4):725-734. PubMed ID: 29368062
[TBL] [Abstract][Full Text] [Related]
9. Role of EGFR SNPs in survival of advanced lung adenocarcinoma patients treated with Gefitinib.
Zhang L; Yuan X; Chen Y; Du XJ; Yu S; Yang M
Gene; 2013 Mar; 517(1):60-4. PubMed ID: 23313300
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor mutation is associated with longer local control after definitive chemoradiotherapy in patients with stage III nonsquamous non-small-cell lung cancer.
Yagishita S; Horinouchi H; Katsui Taniyama T; Nakamichi S; Kitazono S; Mizugaki H; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Sumi M; Shiraishi K; Kohno T; Furuta K; Tsuta K; Tamura T
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):140-8. PubMed ID: 25442336
[TBL] [Abstract][Full Text] [Related]
11. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
[TBL] [Abstract][Full Text] [Related]
12. Tumor burden is predictive of survival in patients with non-small-cell lung cancer and with activating epidermal growth factor receptor mutations who receive gefitinib.
Park JH; Kim TM; Keam B; Jeon YK; Lee SH; Kim DW; Chung DH; Kim YT; Kim YW; Heo DS
Clin Lung Cancer; 2013 Jul; 14(4):383-9. PubMed ID: 23313171
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of the international association for the study of lung cancer/American Thoracic Society/European Respiratory Society classification of lung adenocarcinoma in tumor recurrence and patient survival.
Hung JJ; Yeh YC; Jeng WJ; Wu KJ; Huang BS; Wu YC; Chou TY; Hsu WH
J Clin Oncol; 2014 Aug; 32(22):2357-64. PubMed ID: 24799473
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Role of Subtype Classification in Small-Sized Pathologic N0 Invasive Lung Adenocarcinoma.
Yoshiya T; Mimae T; Tsutani Y; Tsubokawa N; Sasada S; Miyata Y; Kushitani K; Takeshima Y; Murakami S; Ito H; Nakayama H; Okada M
Ann Thorac Surg; 2016 Nov; 102(5):1668-1673. PubMed ID: 27344277
[TBL] [Abstract][Full Text] [Related]
15. Impact of the epidermal growth factor receptor mutation status on the prognosis of recurrent adenocarcinoma of the lung after curative surgery.
Isaka T; Nakayama H; Ito H; Yokose T; Yamada K; Masuda M
BMC Cancer; 2018 Oct; 18(1):959. PubMed ID: 30290774
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation.
Cho SH; Park LC; Ji JH; Park S; Hwang DW; Lee JY; Choi YL; Han JH; Sun JM; Ahn JS; Park K; Ahn MJ
Cancer Chemother Pharmacol; 2012 Aug; 70(2):315-20. PubMed ID: 22760226
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of epidermal growth factor receptor mutations and histologic subtypes with lung adenocarcinoma.
Motono N; Funasaki A; Sekimura A; Usuda K; Uramoto H
Med Oncol; 2018 Jan; 35(3):22. PubMed ID: 29387978
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of heterogeneity in response to retreatment with epidermal growth factor receptor tyrosine kinase inhibitors in patients with lung cancer acquiring secondary resistance to the drug.
Lee Y; Kim HY; Lee SH; Lim KY; Lee GK; Yun T; Han JY; Kim HT; Lee JS
Clin Lung Cancer; 2014 Mar; 15(2):145-51. PubMed ID: 24342626
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant Chemotherapy Improves the Probability of Freedom From Recurrence in Patients With Resected Stage IB Lung Adenocarcinoma.
Hung JJ; Wu YC; Chou TY; Jeng WJ; Yeh YC; Hsu WH
Ann Thorac Surg; 2016 Apr; 101(4):1346-53. PubMed ID: 26794883
[TBL] [Abstract][Full Text] [Related]
20. Direct comparison of 3 PCR methods in detecting EGFR mutations in patients with advanced non-small-cell lung cancer.
Ikeda T; Nakamura Y; Yamaguchi H; Tomonaga N; Doi S; Nakatomi K; Iida T; Motoshima K; Mizoguchi K; Nagayasu T; Tsukamoto K; Kohno S
Clin Lung Cancer; 2012 Sep; 13(5):369-74. PubMed ID: 22410386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
